Navigation Links
Personalised Medicine: An Opportunity for Investment
Date:1/14/2009

LONDON, Jan. 14 /PRNewswire/ -- The pharmaceutical industry is currently facing some key challenges. The increase in drug development costs, a decrease in the number of drugs being approved, and scrutiny from regulatory authorities are forcing companies to look at alternative revenue generators. Patients themselves are also demanding more effective and safer drugs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Pharmacogenomics therefore presents a convincing alternative to guide drug development and therapy. Pharmacogenomics deals with the influence of genetic variations on drug response in patients by correlating gene expression with a drug's efficacy. Personalised medicine is the result of individualised pharmacotherapy, which allows the formulation of drugs that offer appropriate treatment to the right person as needed.

"Recent reports of mishaps taking place due to improper drug metabolism, even when taken at optimal dose, have forced companies to consider individualised medicine more of a necessity than a mere research project," notes Frost & Sullivan (http://www.drugdiscovery.frost.com) Research Analyst Prabakar Sampath. "Every year several hundreds of patients either do not benefit from the treatment they are provided or develop adverse reactions to it. These are compelling reasons enough to pursue personalised medicine as a future directive."

Critics of personalised medicine often suggest that interest in research for a given pharmacogenomics study would decrease because it would only serve a niche market. They contend that a personalised approach would reduce new patient trials for some therapies.

However, a reduction in initial sales will be compensated by greater compliance, leading to higher product use. Frost & Sullivan believes that the commercial feasibility of personalised medicine is not what is gained or lost by moving forward, but what is at stake by not moving forward.

"The desire to meet patients' unmet medical needs, the necessity for product differentiation to gain market share and reimbursement in increasingly crowded markets in several therapeutic areas are forcing companies to invest in pharmacogenomics research," notes Sampath.

Already, genetic testing has been made easy with the increase in availability of reagents and pharmacogenetics services. Diagnostic laboratories are marketing pharmacogenomics services to physicians and in some cases, patients too.

"An ideal application of pharmacogenomics is to integrate it into clinical and nonclinical studies in order to provide value to pharmaceutical R&D by supplementing the information from these studies," says Sampath. "The goal is to provide safer and more efficient medicines, combined with diagnostics, in order to meet the needs of patients."

Pharmacogenomics provides a novel area for product differentiation, competitive advantage, and enhancement of R&D productivity. The pharmaceutical industry is learning how to best apply it in its R&D programs.

Recent initiatives, such as the formation of several pharmacogenomics-focused consortia, new regulatory guidance documents, the introduction of legislative bills and high-profile safety concerns continue to illustrate the prominent role pharmacogenomics will play in moving drug development and therapy from a population-based to an individualized paradigm.

If you are interested in more information on Frost & Sullivan's analysis of drug discovery markets, then send an e-mail to Patrick Cairns, Corporate Communications, at patrick.cairns@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, more details will be provided.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit http://www.frost.com.

    Contact:
    Patrick Cairns
    Corporate Communications - Europe & Africa
    P: +27 18 468 2315
    E: patrick.cairns@frost.com

   http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention
2. U.S. Preventive Medicine: Knowing Risk Factors & Early Detection are Best Strategies for Colon Cancer Prevention
3. Personalizing medicine: New research shows potential of targeted therapies for cancer
4. Measuring medicine: How new technologies could help doctors predict patient outcomes
5. The Changing Face of Medicine: National Medical Fellowships Annual Awards Gala Honors Three Fellows
6. Florida and California Represent Equivalent Areas of Opportunity in the Alzheimers Disease Drug Market
7. Renowned Cancer Researcher Dan Von Hoff, M.D. Advocates for 'The Lost Opportunity in Phase I Oncology Trials'
8. Usher Teams With Body By Milk to Give Teens Once-in-a-Lifetime Opportunity
9. ECPI College of Technology and Medical Careers Institute Announce Extension for South Carolina Military Scholarship Opportunity
10. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
11. HealthMetrix Research Finds Medicare Advantage Plans Offer Seniors Opportunity to Lower Their 2009 Out-of-Pocket Drug Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Dickinson Insurance and Financial ... financial preparation services, is providing an update on a charitable event that began ... Rescue is a locally recognized nonprofit that provides shelter and care for animals ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board ... Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will ... Dr. Puffer’s retirement at the end of 2018. Upon assuming the role of President ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical ... the primary prevention of cardiovascular diseases during the 15th Annual Women’s Health ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out ... free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting ... children of all ages; it is a non-competitive, non-timed event, which is all about ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and ... financial results for the third quarter of 2017 on ... conference call on that day with the investment community ... The conference call will begin at 9 ... can access a live webcast of the conference call ...
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
Breaking Medicine Technology: